Special Edition

Special Edition

Clinical Trials for Rare Diseases

Below, we take a look at ongoing clinical trials for rare diseases. In addition to searching for new therapeutic targets and developing novel drugs...
On location

Clotting Factor Deficiencies Associated With Excess Bleeding Risk, Regardless of Factor Levels

Women who have or are carriers for factor VIII (FVIII) or factor IX (FIX) deficiency often report excessive bleeding, though it is unclear how...

What Can the ASH Trainee Council Do for You? Interview with Sherif M. Badawy,...

The American Society of Hematology created the ASH Trainee Council to advocate for the issues and concerns of hematology/oncology trainees, including mentorship, publishing, and...
ASH Directions

ASH Awards and Programs for Young Hematologists/Oncologists

ASH provides many awards and programs to support hematologists in all stages of their careers. Read on for information about awards specifically geared to...

A Career Timeline for MD Trainees

Every hematologist trainee, whether MD, DO, or PhD, should have a plan for career success. While every person’s career path clearly requires an individualized...

Advice from the Future

We asked innovators and mentors in hematology and oncology: What advice would you give to early-career hematologists? Here’s what they had to say!   “Identify your...

Combo of Ixazomib, Lenalidomide, Dexamethasone Leads to Longer PFS in Relapsed/Refractory Multiple Myeloma

The triplet combination of the oral proteasome inhibitor (PI) ixazomib and the immunomodulatory drugs lenalidomide and dexamethasone resulted in longer progression-free survival (PFS) than...

Targeting Antithrombin: The Key to Achieving Hemostatic Balance in Hemophilia Patients?

Targeting the endogenous anticoagulant antithrombin (AT) in patients with hemophilia restored hemostatic balance and prevented severe bleeding in people with severe forms of the...

Panobinostat Plus Bortezomib and Dexamethasone Safe in Transplant-Eligible Myeloma Patients

The selective histone deacetylase (HDAC) inhibitor panobinostat was safe and effective when used in combination with bortezomib and dexamethasone (RVD) in patients with newly...

Daratumumab Combination Produces Durable Responses in Patients with RRMM

The anti-CD38 monoclonal antibody daratumumab produces durable responses when used in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM), according...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.